Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1 mM EDTA, 4% Trehalose, 1% Mannitol.
Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Reconstitución
Reconstitute in sterile water for a stock solution. Adjust the volume of sterile water so that, after reconstitution, the final stock concentration matches the value indicated on the product label or datasheet.
RECONSTITUTION PROTOCOL
1. Allow the product to be reconstituted and the reconstitution diluent to reach room temperature.
2. Tap or briefly centrifuge the product vial before opening to dislodge any lyophilized material that may be dispersed on the wall or cap of the vial.
3. Use the diluent and stock concentration recommended in the product datasheet. If preparing a stock concentration higher than recommended, contact Technical Service.
4. After adding the diluent, re-cap the vial and invert gently by hand or place on a slow rocking platform to allow the reconstitution diluent to coat all the surfaces inside the vial. Note: Do not mix by vortexing or by pipetting the material up and down.
5. Allow the vial to sit at room temperature with gentle agitation for at least 15 minutes before aliquotting or using.
6. Store the reconstituted material in single use aliquots in polypropylene or siliconized tubes. Aliquots of 10 μL or larger are recommended.
Envío
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Estabilidad y almacenamiento
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Lymphocyte activation gene 3 protein (CD223/LAG3) is a ~56 kDa protein. Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation. Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1. CD223 is the therapeutic target of relatlimab (Opdualag).
1. Workman, CJ. et al. (2002) European journal of immunology 32, 2255-63. PMID: 12209638
2. Workman, CJ. et al. (2002) Journal of immunology (Baltimore, Md. : 1950) 169, 5392-5. PMID: 12421911
3. Workman, CJ. et al. (2003) European journal of immunology 33, 970-9. PMID: 12672063
4. Workman, CJ. et al. (2004) Journal of immunology (Baltimore, Md. : 1950) 172, 5450-5. PMID: 15100286
5. Workman, CJ. et al. (2005) Journal of immunology (Baltimore, Md. : 1950) 174, 688-95. PMID: 15634887
6. Wang, J. et al. (2019) Cell 176, 334-347.e12. PMID: 30580966
7. Maruhashi, T. et al. (2022) Immunity 55, 912-924.e8. PMID: 35413245
中文
English
한국어
日本語
Español
Français
Русский
